Gapping up
In reaction to strong earnings/guidance:
- OLED +14.4%, DT +11.3%, EGHT +10.4%, MIC +9%, SPWR +8.9%, ICD +8.1%, MUSA +7.8%, UCTT +7.7%, SFM +7.5%, MC +7.4%, CRUS +7.3%, INOV +7.2%, HABT +7.2%, ZIXI +7%, NE +6.2%, ABMD +5.9%, ASLN +5.6%, PS +5.4%, LITE +5.4%, NEWM +5.3%, FLWS +5.3%, RCEL +4.8%, HCC +4.3%, CDW +4.2%, KHC +4.2%, FB +4.1%, TDOC +4%, BOOT +3.6%, SPAR +3.6%, LYFT +3.5%, RDN +3.5%, TEN +3.5%, SU +3.3%, ELY +3.2%, HUBG +3.2%, QLYS +3.2%, CATM +3.2%, VAL +3.1%, NVCR +3.1%, MUR +2.8%, SRCL +2.8%, TREE +2.7%, AME +2.7%, HTGC +2.6%, GPN +2.5%, APO +2.4%, FORM +2.3%, ZNGA +2.3%, AKRX +2.3%, PRAH +2.2%, SBUX +2.1%, TKR +2.1%, ADM +2.1%, ROG +2%, CI +2%, AHH +1.9%, GNRC +1.9%, MNTA +1.9%, PPC +1.8%, CG +1.7%, AGI +1.6%, AXTI +1.6%, STAG +1.6%, MO +1.6%, AAPL +1.4%, OII +1.3%, PCTY +1.2%, ING +1.1%, INGR +1.1%, EQT +1%, NTLA +1%
Other news:
- DRNA +11.2% (to receive $200 million up front plus up to $1.47 billion in potential milestone payments related to DCR-HBVS from Roche)
- MIC +9% (to actively pursue strategic alternatives including a sale of the company or its operating businesses as a means of unlocking value for shareholders)
- BJ +6.2% (to join S&P MidCap 400)
- ALDX +6% (announces expanded results from allergen chamber clinical methods trial of topical ocular reproxalap in patients with allergic conjunctivitis, and Phase 3 clinical trial plans)
- REPH +4.9% (granted appeal from FDA regarding Complete Response Letter relating to the New Drug Application seeking approval for intravenous meloxicam)
- FCAU +3.2% (Fiat Chrysler and Groupe PSA to join together in merger of equals; aslo released earnings)
- CDAY +2% (to join S&P MidCap 400)
- OII +1.3% (to join S&P SmallCap 600)
- WING +0.9% (ongoing earnings volatility; also CEO interview was on CNBC MadMoney)
- CVET +0.9% (to join S&P SmallCap 600)
Analyst comments:
- TTPH +10.9% (upgraded to Buy from Hold at Gabelli & Co)
- EAT +1.5% (upgraded to Overweight from Neutral at Piper Jaffray)